Rigel Pharmaceuticals (RIGL) Q3 FY2026 earnings: revenue $81 million, up 16.5% on the year

Rigel Pharmaceuticals Inc. (RIGL) reported revenue of $81 million for Q3 FY2026, the quarter ended 30 September 2026, up 16.5% on the same quarter a year earlier. Net income was $13 million, down 52.7% on the year, and diluted earnings per share $0.65. The figures are the company's own, from the 10-Q it filed with the SEC on 5 November 2026.

Revenue

$81 million

+16.5% on the year · +2.8% on the quarter

Q4 FY2024Q3 FY2026

Operating margin

21.1%

40.9% a year earlier

Q4 FY2024Q3 FY2026

Net income

$13 million

-52.7% on the year · -23.7% on the quarter

Q4 FY2024Q3 FY2026

Diluted EPS

$0.65

-55.5% on the year · -26.1% on the quarter

Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

What management said

Guidance figures: 1 raised, 2 narrowed.

Product sales and total revenue grew: Total revenues were $80.9 million, of which net product sales were $72.3 million, up 13% from $64.1 million a year earlier. Contract revenues from collaborations were $8.6 million.
Third-quarter net income declined: Net income was $13.2 million, or $0.65 diluted per share, against $27.9 million, or $1.46 diluted per share, a year earlier.
Launch began August 13: VEPPANU became commercially available in the U.S. on August 13, 2026, following the license agreement that took effect on June 11, 2026.

Read the earnings call summary

Income statement (profit and loss)

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Revenue	80.9	78.7	69.5	+2.8%	+16.5%
Cost of revenue	10.8	8.5	4.8	+26.5%	+126.9%
Gross profit	70.1	70.2	64.7	-0.1%	+8.3%
Gross margin	86.7%	89.2%	93.2%
Research and development	18.3	14.0	7.4	+30.9%	+148.5%
Selling, general and administrative	34.7	32.6	28.9	+6.4%	+20.0%
Operating income	17.1	23.6	28.4	-27.4%	-39.8%
Operating margin	21.1%	30.0%	40.9%
Interest expense	0.3	0.8	1.9	-67.0%	-86.4%
Pre-tax income	17.4	23.6	27.6	-26.2%	-37.0%
Income tax	4.2	6.3	-0.3	-32.9%
Effective tax rate	24.3%	26.7%	-1.0%
Net income	13.2	17.3	27.9	-23.7%	-52.7%
Net margin	16.3%	22.0%	40.2%
Diluted EPS	$0.65	$0.88	$1.46	-26.1%	-55.5%

$ million except per share.

Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Operating cash flow	34.6	30.7	24.0	+12.8%	+43.8%
Cash from investing	-18.4	17.5	-33.2
Cash from financing	-30.3	-11.7	4.3
Depreciation and amortisation	1.8	0.8	0.6	+111.4%	+197.3%
Share-based compensation	4.9	6.8	3.4	-29.1%	+44.3%
Buybacks	1.0	0.5	0.0	+100.4%
Diluted shares, weighted	20m	20m	19m	+4.4%	+6.7%
Shares outstanding at period end	19m	19m	18m	+0.8%	+3.7%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Shareholders' equity	445	425	118	+4.6%	+278.5%
Debt	8.0	40.0	60.0	-80.0%	-86.7%
Operating lease liabilities	0.0	0.1	0.6
Other liabilities	70.8	55.6	64.4	+27.3%	+9.9%
Total liabilities and equity	524	521	243	+0.5%	+116.0%
Fixed assets	n/a	n/a	0.1
Intangible assets	94.6	93.9	25.3	+0.8%	+273.3%
Investments	74.1	34.5	88.6	+114.6%	-16.4%
Cash and equivalents	46.6	60.8	48.5	-23.3%	-3.9%
Receivables	56.5	56.0	45.9	+0.7%	+22.9%
Inventory	15.8	14.4	13.3	+10.0%	+18.8%
Other assets	236	261	20.8	-9.6%	+1,037.6%
Total assets	524	521	243	+0.5%	+116.0%

Questions

What was Rigel Pharmaceuticals' revenue in Q3 FY2026?

Rigel Pharmaceuticals (RIGL) reported revenue of $81 million for Q3 FY2026, the quarter ended 30 September 2026, up 16.5% on the same quarter a year earlier.

How much did Rigel Pharmaceuticals earn in Q3 FY2026?

Net income for Q3 FY2026 was $13 million, down 52.7% on the year, and diluted earnings per share $0.65.

When did Rigel Pharmaceuticals report Q3 FY2026 results?

Rigel Pharmaceuticals filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 5 November 2026.

Quarterly results, the last 20 quarters

	Q4 FY2021 *	Q1 FY2022	Q2 FY2022	Q3 FY2022	Q4 FY2022 *	Q1 FY2023	Q2 FY2023	Q3 FY2023	Q4 FY2023 *	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024 *	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025 *	Q1 FY2026	Q2 FY2026	Q3 FY2026
Revenue	20.4	16.7	29.8	22.4	51.3	26.1	26.9	28.1	35.8	29.5	36.8	55.3	57.6	53.3	102	69.5	69.8	58.8	78.7	80.9
Cost of revenue	0.5	0.1	1.0	0.2	0.3	1.0	1.1	1.3	3.8	2.0	2.8	8.0	5.8	4.4	4.5	4.8	6.0	4.6	8.5	10.8
Gross profit	19.9	16.6	28.8	22.2	50.9	25.1	25.8	26.9	32.0	27.5	34.0	47.3	51.8	48.9	97.2	64.7	63.8	54.2	70.2	70.1
Gross margin	98%	99%	97%	99%	99%	96%	96%	95%	89%	93%	92%	85%	90%	92%	96%	93%	91%	92%	89%	87%
R&D	13.3	15.5	14.8	14.7	15.4	10.1	4.8	6.5	3.2	6.0	5.5	6.2	5.6	8.4	6.8	7.4	10.7	11.7	14.0	18.3
SG&A	24.5	27.4	27.0	25.9	32.2	27.7	26.3	24.9	26.9	28.4	28.0	27.0	29.5	27.7	29.3	28.9	30.0	30.7	32.6	34.7
Operating income	-21.4	-26.3	-13.0	-18.4	2.1	-12.7	-5.3	-4.5	2.0	-7.0	0.4	14.1	16.7	12.8	61.1	28.4	23.2	11.9	23.6	17.1
Operating margin	-105%	-157%	-43%	-82%	4%	-49%	-20%	-16%	5%	-24%	1%	25%	29%	24%	60%	41%	33%	20%	30%	21%
Interest expense	1.3	1.2	0.6	0.8	1.1	1.2	1.9	1.9	1.9	1.9	2.0	2.1	2.0	1.9	1.9	1.9	1.7	1.4	0.8	0.3
Pre-tax income	-22.7	-27.4	-13.5	-19.0	1.4	n/a	n/a	n/a	n/a	-8.2	-1.0	12.4	15.2	11.5	60.0	27.6	22.7	11.7	23.6	17.4
Tax rate	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0%	6%	1%	1%	-1%	-1080%	26%	27%	24%
Net income	-22.6	-27.4	-13.5	-19.0	1.4	-13.5	-6.6	-5.7	0.7	-8.2	-1.0	12.4	14.3	11.4	59.6	27.9	268	8.7	17.3	13.2
Net margin	-111%	-164%	-45%	-85%	3%	-52%	-25%	-20%	2%	-28%	-3%	22%	25%	21%	59%	40%	384%	15%	22%	16%
Diluted EPS	-$1.30	-$1.60	-$0.80	-$1.10	$0.10	-$0.80	-$0.40	-$0.30	$0.00	-$0.50	-$0.06	$0.70	$0.80	$0.63	$3.28	$1.46	$13.54	$0.44	$0.88	$0.65
Operating cash flow	-19.1	-25.6	-12.9	-13.3	-21.9	-4.1	5.9	-1.4	-6.2	-5.0	0.3	21.7	14.5	-0.9	30.5	24.0	22.0	2.7	30.7	34.6
Capital expenditure	n/a	0.2	n/a	0.2	0.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Free cash flow	n/a	-25.9	n/a	-13.5	-22.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Buybacks	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0.0	0.0	0.0	n/a	3.7	0.5	1.0
Shares outstanding	17m	17m	17m	17m	17m	17m	17m	17m	17m	18m	18m	18m	18m	18m	18m	18m	18m	19m	19m	19m
Filing	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q

Each quarter as filed, linked to its filing.

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 September 2026, filed 5 November 2026: the filing.